SCHEMBL15469407

SCHEMBL15469407

Cc1ccc([C@@]2(NC(=O)c3ccncc3)CCOc3cccnc32)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPM8 Q7Z2W7 1/20 0.52
FPR2 P25090 1/20 0.40
GRM5 P41594 1/20 0.40
RAB9A P51151 7/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
HSD17B10 Q99714 1/20 0.37
PTGS2 P35354 1/20 0.37
NPC1 O15118 5/20 0.36
FNTA P49354 1/20 0.36
FNTB P49356 1/20 0.36
GAA P10253 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
CA1 P00915 1/20 0.35
CA9 Q16790 1/20 0.35
DYRK1A Q13627 1/20 0.35
NAMPT P43490 1/20 0.34
KDM4E B2RXH2 1/20 0.34
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
ROCK2 O75116 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15467342 0.93 TRPM8 (0.53) TRPM8RAB9ASMN1; SMN2PTGS2NPC1
SCHEMBL15467345 0.93 TRPM8 (0.53) TRPM8RAB9ASMN1; SMN2PTGS2NPC1
SCHEMBL15466948 0.90 TRPM8 (0.57) TRPM8RAB9ASMN1; SMN2HSD17B10
SCHEMBL15466947 0.90 TRPM8 (0.57) TRPM8RAB9ASMN1; SMN2HSD17B10
SCHEMBL15469410 0.90 TRPM8 (0.51) TRPM8RAB9ASMN1; SMN2PTGS2NPC1
SCHEMBL15469370 0.90 TRPM8 (0.55) TRPM8RAB9ANPC1GAAL3MBTL1
SCHEMBL15469399 0.89 TRPM8 (0.50) TRPM8RAB9ASMN1; SMN2NPC1GAA
SCHEMBL15469394 0.87 TRPM8 (0.46) TRPM8FPR2GRM5RAB9ASMN1; SMN2
SCHEMBL16418807 0.86 TRPM8 (0.49) TRPM8RAB9ASMN1; SMN2NPC1DYRK1A
SCHEMBL16418825 0.86 TRPM8 (0.54) TRPM8RAB9ANPC1DYRK1AROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8952009-B2 Chroman derivatives as TRPM8 inhibitors AMGEN INC. (US) 2015-02-10 US disclosed
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC (US) 2015-01-29 US disclosed
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS AMGEN INC. (US) 2014-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150031668-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885FPR2 1302/4885GRM5 393/4885
US-20140045855-A1 CHROMAN DERIVATIVES AS TRPM8 INHIBITORS TRPM8, TRPM5, TRPM7 TRPM8 1/4885FPR2 1302/4885GRM5 393/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.